tetano
Editor, Senior Moderator
Vaccine
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.12.023 | How to Cite or Link Using DOI
Permissions & Reprints
Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients
Paungpaga Lertdumrongluka, Corresponding Author Contact Information, E-mail The Corresponding Author, Siribha Changsirikulchaib, Chutatip Limkunakula, Poonsuk Prachukthuma, Prapaipun Punpiputa, Rungtiva Buppanharuna, Chuencheevit Chotpitayasunondha
Purchase
a Department of Medicine, Srinakarinwirot University, Royal Irrigation Hospital, 222, Tiwanon Road, Kwang Bangtalat, Pakkret, Nonthaburi, Thailand
b Department of Medicine, Srinakarinwirot University, The HRH Princess Maha Chakri Sirindhorn Medical Center, Nakhonnayok, Thailand
Received 13 September 2011; revised 29 November 2011; Accepted 3 December 2011. Available online 15 December 2011.
Abstract
A worldwide vaccination campaign against the 2009 pandemic influenza A (H1N1) virus was launched among high-risk subjects, including hemodialysis patients. The long-term immunogenicity of an influenza vaccine has not been investigated in hemodialysis patients. This study aimed to (1) assess the long-term immunogenicity of a monovalent non-adjuvanted influenza A (H1N1) vaccine in hemodialysis patients and (2) determine the safety of this vaccine. We conducted a prospective cohort study of 44 hemodialysis patients and 149 healthy controls in 2010. All of the participants received a single dose of the monovalent non-adjuvanted 2009 influenza A (H1N1) vaccine. The level of antibodies was measured at baseline and at 4 and 24 weeks post-vaccination using a hemagglutination inhibition assay. The outcomes were the percentages of participants who achieved seroconversion and seroprotection (titer ≥1:40) 4 and 24 weeks after vaccination. At 4 weeks post-vaccination, seroconversion was observed in 17 (38.6%) of the hemodialysis patients and 94 (63.1%) of the controls (P = 0.056), and protective titers were obtained in 22 (50%) of the hemodialysis patients and 100 (67.1%) of the controls (P = 0.426). At 24 weeks post-vaccination, immunogenicity decreased in both the hemodialysis patients and the controls, but there were no significant differences between the hemodialysis patients and the controls in the seroconversion rate (27.3% versus 36.9%, P = 0.526) or the seroprotection rate (38.6% versus 48.3%, P = 0.996). No differences in adverse events were observed between the hemodialysis patients and the controls. In summary, the 2009 influenza A (H1N1) vaccine elicits a similar immune response in both hemodialysis patients and healthy controls, but immunity declines 24 weeks after vaccination in both groups. Hemodialysis patients should at least be vaccinated annually against the influenza virus.
Highlights
► We study long-term immunogenicity of influenza vaccine in hemodialysis patients. ► Immunogenicity was similar in hemodialysis patients and controls. ► Immunogenicity declined by 24 weeks after vaccination in hemodialysis patients.
http://www.sciencedirect.com/science/article/pii/S0264410X11019463
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.12.023 | How to Cite or Link Using DOI
Permissions & Reprints
Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients
Paungpaga Lertdumrongluka, Corresponding Author Contact Information, E-mail The Corresponding Author, Siribha Changsirikulchaib, Chutatip Limkunakula, Poonsuk Prachukthuma, Prapaipun Punpiputa, Rungtiva Buppanharuna, Chuencheevit Chotpitayasunondha
Purchase
a Department of Medicine, Srinakarinwirot University, Royal Irrigation Hospital, 222, Tiwanon Road, Kwang Bangtalat, Pakkret, Nonthaburi, Thailand
b Department of Medicine, Srinakarinwirot University, The HRH Princess Maha Chakri Sirindhorn Medical Center, Nakhonnayok, Thailand
Received 13 September 2011; revised 29 November 2011; Accepted 3 December 2011. Available online 15 December 2011.
Abstract
A worldwide vaccination campaign against the 2009 pandemic influenza A (H1N1) virus was launched among high-risk subjects, including hemodialysis patients. The long-term immunogenicity of an influenza vaccine has not been investigated in hemodialysis patients. This study aimed to (1) assess the long-term immunogenicity of a monovalent non-adjuvanted influenza A (H1N1) vaccine in hemodialysis patients and (2) determine the safety of this vaccine. We conducted a prospective cohort study of 44 hemodialysis patients and 149 healthy controls in 2010. All of the participants received a single dose of the monovalent non-adjuvanted 2009 influenza A (H1N1) vaccine. The level of antibodies was measured at baseline and at 4 and 24 weeks post-vaccination using a hemagglutination inhibition assay. The outcomes were the percentages of participants who achieved seroconversion and seroprotection (titer ≥1:40) 4 and 24 weeks after vaccination. At 4 weeks post-vaccination, seroconversion was observed in 17 (38.6%) of the hemodialysis patients and 94 (63.1%) of the controls (P = 0.056), and protective titers were obtained in 22 (50%) of the hemodialysis patients and 100 (67.1%) of the controls (P = 0.426). At 24 weeks post-vaccination, immunogenicity decreased in both the hemodialysis patients and the controls, but there were no significant differences between the hemodialysis patients and the controls in the seroconversion rate (27.3% versus 36.9%, P = 0.526) or the seroprotection rate (38.6% versus 48.3%, P = 0.996). No differences in adverse events were observed between the hemodialysis patients and the controls. In summary, the 2009 influenza A (H1N1) vaccine elicits a similar immune response in both hemodialysis patients and healthy controls, but immunity declines 24 weeks after vaccination in both groups. Hemodialysis patients should at least be vaccinated annually against the influenza virus.
Highlights
► We study long-term immunogenicity of influenza vaccine in hemodialysis patients. ► Immunogenicity was similar in hemodialysis patients and controls. ► Immunogenicity declined by 24 weeks after vaccination in hemodialysis patients.
http://www.sciencedirect.com/science/article/pii/S0264410X11019463